(S)-3-(2-ethylphenoxy)propane-1,2-diol | 1092799-92-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (S)-3-(2-ethylphenoxy)propane-1,2-diol
• 英文别名: (2S)-3-(2-ethylphenoxy)propane-1,2-diol
• CAS: 1092799-92-2
• 化学式: C₁₁H₁₆O₃
• 分子量: 196.246
• InChiKey: KLIWBPMQXVJEAN-JTQLQIEISA-N

物化性质

• 熔点：
  68-70 °C(Solv: hexane (110-54-3))
• 沸点：
  349.3±27.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-3-(2-ethylphenoxy)propane-1,2-diol 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以51.8%的产率得到(S)-1-(2'-ethylphenoxy)-2,3-epoxypropane
  参考文献：
  名称：

  Synthesis of all of the stereoisomers of β3-adrenoceptor antagonist SR 59230 based on the spontaneous resolution of 3-(2-ethylphenoxy)propane-1,2-diol

  摘要：

  Racemic 3-(2-ethylphenoxy)propane-1,2-diol 2 has been effectively resolved into (S)- and (R)-enantiomers by a preferential crystallization procedure. Non-racemic diols 2, obtained via a Mitsunobu reaction, have been converted into the non-racemic 1,2-epoxy-3-(2-ethylphenoxy)propanes (S)- and (R)-5 and then into non-racemic 3-(2-ethylphenoxy)-1(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanols 1. The characteristics of all four stereoisomers, (S,S)-1 (SR 59230), (R,R)-1 (SR 59483), (R,S)-1 and (S,R)-1 (SR 59231) and their hydrogen oxalates with a 1:1 composition have been presented. The crystalline oxalates (S,S)-1 center dot C2H2O4 (SR 59230A) and (R,S)-1 center dot 0.5C(2)H(2)O(4) were studied by single crystal X-ray diffraction. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2016.05.001
• 作为产物：
  描述：

  乙基苯酚 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 4.67h， 生成 (S)-3-(2-ethylphenoxy)propane-1,2-diol
  参考文献：
  名称：

  一系列均匀取代的苯基甘油醚中的三种不同类型的手性驱动结晶。

  摘要：

  七个手性芳基甘油醚2-RC（6）H（4）-O-CH（2）CH（OH）CH（2）OH（R ​​= H，Me，Et，烯丙基，n-Pr，i-Pr，叔-Bu）以外消旋和垢的形式合成。测量了每个物种的外消旋和尺度样品的红外光谱，熔点和熔融焓，导出了液态混合的对映异构体的熵和外消旋化合物形成的Gibbs自由能，并重建了二元相图。整个家族。对这四种物质的固态外消旋化合物稳定性进行了排名。建立了注册手性药物美芬素及其乙基类似物的自发拆分。在叔丁基衍生物的溶液结晶过程中，形成了亚稳态异常聚集体，形成了在晶胞中具有三个独立的R *和一个独立的S *分子的晶体。

  DOI：

  10.1002/chir.20648

文献信息

• Three different types of chirality-driven crystallization within the series of uniformly substituted phenyl glycerol ethers
  作者：Alexander A. Bredikhin、Zemfira A. Bredikhina、Victorina G. Novikova、Alexander V. Pashagin、Dmitry V. Zakharychev、Aidar T. Gubaidullin

  DOI：10.1002/chir.20648

  日期：2008.10

  derived and binary phase diagrams were reconstructed for the whole family. Solid racemic compounds stabilities were ranked for the four substances. Spontaneous resolution was established for the registered chiral drug mephenesin and its ethyl analogue. Metastable anomalous conglomerate, forming crystals having three independent R* and one independent S* molecules in the unit cell, is formed during solution

  七个手性芳基甘油醚2-RC（6）H（4）-O-CH（2）CH（OH）CH（2）OH（R ​​= H，Me，Et，烯丙基，n-Pr，i-Pr，叔-Bu）以外消旋和垢的形式合成。测量了每个物种的外消旋和尺度样品的红外光谱，熔点和熔融焓，导出了液态混合的对映异构体的熵和外消旋化合物形成的Gibbs自由能，并重建了二元相图。整个家族。对这四种物质的固态外消旋化合物稳定性进行了排名。建立了注册手性药物美芬素及其乙基类似物的自发拆分。在叔丁基衍生物的溶液结晶过程中，形成了亚稳态异常聚集体，形成了在晶胞中具有三个独立的R *和一个独立的S *分子的晶体。
• A Smart Library of Epoxide Hydrolase Variants and the Top Hits for Synthesis of (<i>S</i>)-β-Blocker Precursors
  作者：Xu-Dong Kong、Qian Ma、Jiahai Zhou、Bu-Bing Zeng、Jian-He Xu

  DOI：10.1002/anie.201402653

  日期：2014.6.23

  the enzyme active pocket has led to a smart library of epoxide hydrolase variants with an expanded substrate spectrum covering a series of typical β‐blocker precursors. Improved activities of 6‐ to 430‐fold were achieved by redesigning the active site at two predicted hot spots. This study represents a breakthrough in protein engineering of epoxide hydrolases and resulted in enhanced activity toward

  酶活性口袋的微调已形成了环氧水解酶变体的智能库，其底物光谱范围扩大，涵盖了一系列典型的β-受体阻滞剂前体。通过在两个预计的热点上重新设计活动站点，可以将活动提高6到430倍。这项研究代表了环氧化物水解酶蛋白质工程的一项突破，并提高了对庞大底物的活性。
• SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20180186801A1

  公开（公告）日：2018-07-05

  Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
• US9957271B2
  申请人：——

  公开号：US9957271B2

  公开（公告）日：2018-05-01
• Synthesis of all of the stereoisomers of β3-adrenoceptor antagonist SR 59230 based on the spontaneous resolution of 3-(2-ethylphenoxy)propane-1,2-diol
  作者：Zemfira A. Bredikhina、Alexey V. Kurenkov、Dmitry B. Krivolapov、Alexander A. Bredikhin

  DOI：10.1016/j.tetasy.2016.05.001

  日期：2016.7

  Racemic 3-(2-ethylphenoxy)propane-1,2-diol 2 has been effectively resolved into (S)- and (R)-enantiomers by a preferential crystallization procedure. Non-racemic diols 2, obtained via a Mitsunobu reaction, have been converted into the non-racemic 1,2-epoxy-3-(2-ethylphenoxy)propanes (S)- and (R)-5 and then into non-racemic 3-(2-ethylphenoxy)-1(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanols 1. The characteristics of all four stereoisomers, (S,S)-1 (SR 59230), (R,R)-1 (SR 59483), (R,S)-1 and (S,R)-1 (SR 59231) and their hydrogen oxalates with a 1:1 composition have been presented. The crystalline oxalates (S,S)-1 center dot C2H2O4 (SR 59230A) and (R,S)-1 center dot 0.5C(2)H(2)O(4) were studied by single crystal X-ray diffraction. (C) 2016 Elsevier Ltd. All rights reserved.